Company Profile

Symbio Pharmaceuticals (OTC: SYMQY)
1:42 PM UTC, 05/20/24
Last: $1.21 Change: +0.00 %Change: +0.00% Volume: 100
Detailed Quote
Open: $ 1.21   Volume: 100
High: $ 1.21   Yield(%) n/a
Low: $ 1.21   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 26,113.00
EPS ($) n/a   Shares Out: 26,113.00
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): n/a
% Price Change (last 13 weeks): n/a
% Price Change (last 26 weeks): n/a
% Price Change (last 52 weeks): n/a
% Price Change (year to date): n/a
Management Effectiveness
Return on Equity (%): n/a
Return on Assets (%): n/a
Return on Invested Capital (%): n/a
Profitability
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): n/a
Price & Volume
50-day Moving Average: $n/a
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): n/a
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $2.92
52-wk low: $1.21
Bid: $n/a
Ask: $n/a
Company Information
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded by Fuminori Yoshida on March 25, 2005 and is headquartered in Tokyo, Japan.
Symbio Pharmaceuticals
Toranomon 30 Mori Building 3-2-2 Toranomon Minato-Ku
Tokyo TY 105-0001

Phone: 81.3.5472.1125
Fax: 81.3.5472.3054
http://www.symbiopharma.com
Per Share Data
Earnings (1year) ($): n/a
Annual Dividend ($): n/a
Current P/E Ratio (ttm): n/a
Book Value ($): n/a
Cash Flow ($): n/a
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): n/a
Price/Book (x): n/a
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): n/a
Current Ratio (x): n/a
LT Debt/Equity (x): n/a
Total Debt/Equity (x): n/a



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.